A lot of drugs, such as renin inhibitors, ACE inhibitors and AT1 receptor antagonists, aiming at interfering with the RAAS signaling have been put into wide clinical administration for PAH treatment [27]. This evidence concerns the gene REN and pulmonary arterial hypertension.